It's Back to the Future for the EPO Divisional Application Deadline Rules

21 October 2013 PharmaPatents Blog

The EPO has announced that it is changing the EPO divisional application deadline rules to eliminate the current 24-month deadline for filing divisional applications, and permit the filing of a divisional application as long as the parent application still is pending. The change will apply to divisional applications filed on or after April 1, 2014.

The EPO Announcement

The EPO announcement was published on October 18, 2013, and simply states:

The Administrative Council has adopted in its meeting of October an amendment of the provisions of the European Patent Convention dealing with the requirements for the filing of divisional applications, namely Rules 36, 38, and 135.

The decision enters into force on 1. April 2014 and will apply to divisional applications filed on or after that date. It enables the filing of divisional applications as long as the earlier (parent) application is pending. The 24-month time limits for the filing of divisional applications are repealed.

In addition, there will be an additional fee as part of the filing fee for divisional applications of second or subsequent generation. This means that the filing of divisional applications in respect of earlier divisional applications will be subject to an additional fee. The amounts of this fee grow progressively with each subsequent generation of divisional applications up to a certain level, becoming then a flat fee.

Reopening The Window

Because the rule change applies to divisional applications filed on or after April 1, 2014, it appears that it will permit applicants to file a divisional application where the current 24-month period for doing so already has passed, as long as the parent application still is pending in April. Applicants who would like to take advantage of this change with a parent application that is close to allowance (or other termination of proceedings) may want to consider extending response deadlines and/or taking advantage of the EPO’s “further processing” provisions to prolong the pendency of the parent application through April 1.

Applicants interested in learning how this change impacts their European patent applications should seek the advice of European patent counsel.

A Welcome Change

This change likely will be welcomed by most applicants, who usually prefer to wait to file a divisional application until they know what subject matter will be allowed in the original application. In addition to spreading out patent costs, that timing often permits applicants to leverage strategies that were successful in the original application when prosecuting the divisional application. Further, this change will eliminate the need to file a “back up” divisional application when it is still possible that the original application will be allowed. The increasing fee structure is an interesting twist, but not unlike the USPTO fee structure that imposes escalating fees for subsequent Requests for Continued Examination (RCEs).

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services

Insights

CMS Proposes Enhanced Scrutiny over Medicaid Supplemental Payments
20 November 2019
Health Care Law Today
The Purpose of a Corporation
November 2019
Legal News: Business Law
Should This Be a "Mobility" Industry Blog?
19 November 2019
Dashboard Insights
Data Processing Patent Eligibility: Federal Circuit Finds Claims Eligible in KPN v. Gemalto
19 November 2019
IP Litigation Current
PATH Summit 2019
18-20 December 2019
Arlington, VA
Madison CLE Days
18-19 December 2019
Madison, WI
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
HFMA MA-RI Annual Compliance Update
12 December 2019
Boston, MA